Global X China Biotech Innovation ETF
CHB was delisted on the 16th of February, 2024.
3 hedge funds and large institutions have $127K invested in Global X China Biotech Innovation ETF in 2022 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, reducing their positions, and 0 closing their positions.
2,440% more capital invested
Capital invested by funds: $5K → $127K (+$122K)
50% more funds holding
Funds holding: 2 → 3 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
+$133K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$13.7K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $111K | +$133K | +13,229 | New |
|
|
2
UBS Group
Zurich,
Switzerland
| $13K | +$13.7K | +1,361 | +674% |
|
|
BBPWM
3
Blue Bell Private Wealth Management
Blue Bell,
Pennsylvania
| $3K | – | – | – |
|
CHB Hedge Fund Activity: Q3 2022 in Review
3 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Global X China Biotech Innovation ETF (CHB) for Q3 2022, worth a combined $127K — up 2,440% from $5K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new CHB positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.
The largest buyer was Jane Street, opening a new position worth an estimated $133K.
- 3 institutional investors held Global X China Biotech Innovation ETF (CHB) as of Q3 2022, up from 2 in Q2 2022.
- Funds reported $127K of Global X China Biotech Innovation ETF stock for Q3 2022, up 2,440% quarter-over-quarter.
- 1 fund opened new Global X China Biotech Innovation ETF positions in Q3 2022 and 0 closed out, a net change of +1 holder.
- The largest Global X China Biotech Innovation ETF buyer in Q3 2022 was Jane Street, an estimated $133K added.
Based on aggregated 13F filings for Q3 2022.